Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

ASND Ascendis Pharma AS

135,10

-2,35 (-1,71%)

01 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

0000950170-24-012212.txt

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Ascendis Pharma AS Charts.

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Ascendis Pharma AS Charts.

News Ascendis Pharma AS

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Freitag 31 Mai 2024 (19 Stunden vor) • Edgar (US Regulatory)

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
Donnerstag 30 Mai 2024 (2 Tage vor) • GlobeNewswire Inc.

Form SD - Specialized disclosure report
Mittwoch 29 Mai 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 16 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 14 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
Dienstag 14 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
Montag 13 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
Donnerstag 9 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Ascendis Pharma Reports First Quarter 2024 Financial Results
Donnerstag 2 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Donnerstag 25 April 2024 (1 Monat vor) • GlobeNewswire Inc.

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Mittwoch 24 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Donnerstag 7 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere Ascendis Pharma AS News-Artikel

District Metals

Amerigo Resources

Arrowhead Pharmaceuticals

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen